A big piece of the pie
April 2020

LONDON—GlobalData, a leading data and analytics company, shared in a recent report that oncology ranked as the top therapy field for non-industry sponsored clinical trials last year, accounting for 25.7 percent of all clinical trials. Central nervous system conditions, cardiovascular, infectious disease and metabolic disorders followed, accounting for 23.5 percent, 8.9 percent, 8.5 percent and 7.4 percent, respectively. Of those, all but metabolic disorders saw growth from 2018 to 2019. Scotty Chung-Siu, senior analyst at GlobalData, commented that “When looking at non-industry-sponsored clinical trials since 2017, there has been a steady increase, from 32.1 percent of all clinical trials that year to 34.5 percent in 2019.” Chung-Siu added that “Phase 2 clinical trials made up 49.7 percent of all clinical trials in 2019, with Phase 4 following with 19.4 percent, Phase 1 next with 16.4 percent, and Phase 3 with 14.5 percent.”

1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.